Global Cancer Therapeutics Market Report and Forecast 2023-2031

Global Cancer Therapeutics Market Report and Forecast 2023-2031


Global Cancer Therapeutics Market Outlook


The global cancer therapeutics market size attained a value of USD 135.8 billion in 2022. The market is anticipated to grow at a CAGR of 10.4% during the forecast period of 2023-2031 to attain a value of USD 330.8 billion by 2031.

Cancer Therapeutics Market: Introduction


Cancer therapeutics refers to a broad range of medical strategies, treatments, and modalities aimed at treating cancer, controlling its spread, and managing associated symptoms. The primary goal is to either eliminate the disease or significantly improve the patient's quality of life. There are several main categories of cancer therapeutics, each with its own specific uses:
  • Surgery: This is often the first line of treatment, particularly when the cancer is localized. The aim is to physically remove the tumour and sometimes the surrounding tissue.
  • Radiation Therapy: This involves using high-energy radiation to kill or shrink cancer cells. It can be used as a standalone treatment or in conjunction with other modalities like surgery or chemotherapy.
  • Chemotherapy: This refers to the use of drugs to kill or slow the growth of cancer cells. Chemotherapy can be systemic (affecting the whole body) or localized (targeting a specific area).
  • Targeted Therapy: These are drugs or other substances that block the growth of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. Targeted therapies can cause less harm to normal cells compared to chemotherapy and radiation therapy.
  • Immunotherapy: This type of therapy boosts the body's natural defences to fight cancer. It uses substances made by the body or in a lab to improve, target, or restore immune system function.
  • Hormone Therapy: Some cancers, like breast and prostate cancer, are sensitive to hormones. Hormone therapy involves removing or blocking the action of these hormones, thereby inhibiting cancer growth.
  • Stem Cell Transplant: This procedure involves replacing unhealthy bone marrow with healthy stem cells that can grow into new marrow. It is usually used in conjunction with high-dose chemotherapy or radiation therapy.
  • Precision Medicine: Also known as personalized medicine, this approach tailor’s treatment to the genetic changes in a person's cancer cells. This includes treatments like CAR-T cell therapies, which involve modifying a patient's own immune cells to treat their cancer.
Each of these categories of cancer therapeutics has its own uses and can be employed alone or in combination, depending on the type and stage of the cancer, as well as the overall health of the patient. The decision to use a certain type of therapy is made based on a detailed evaluation of the patient and the characteristics of the cancer.

Cancer Therapeutics Market Segmentations


The market can be categorised into therapy type, drug class, route of administration, cancer type, distribution channel, and region

Cancer Therapeutics Market Breakup by Therapy type
  • Chemotherapy
  • Immunotherapy
1. Checkpoint Inhibitors

2. Car-T Cell Therapy

3. Cancer Vaccines

4. Cytokine Therapy
  • Targeted Therapy
1. Tyrosine Kinase Inhibitors

2. Monoclonal Antibodies

3. Proteasome Inhibitors
  • Hormonal Therapy
  • Radiation Therapy
  • Stem Cell Transplant
  • Gene Therapy
  • Other Emerging Therapies
Cancer Therapeutics Market Breakup by Drug class
  • Alkylating Agents
  • Antimetabolites
  • Antitumor Antibiotics
  • Topoisomerase Inhibitors
  • Mitotic Inhibitors
  • Hormone Therapies
  • Immune Checkpoint Inhibitors
  • Others
Cancer Therapeutics Market Breakup by Route of administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Topical
  • Others
Cancer Therapeutics Market Breakup by Cancer type
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Skin Cancer
  • Blood Cancer (Leukemia, Lymphoma, etc.)
  • Gastrointestinal Cancer
  • Gynecological Cancer
  • Others
Cancer Therapeutics Market Breakup by Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Specialty pharmacies
Cancer Therapeutics Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Cancer Therapeutics Market Scenario


The global cancer therapeutics market continues to show robust growth, driven by increasing incidence of various types of cancer, advancements in cancer research, and escalating investment in drug development. As of 2023, the market has been shaped by a variety of factors, including innovation in drug discovery, precision medicine, and growing awareness about early detection and diagnosis of cancer.

Industry Trends

In terms of regional distribution, North America holds the largest market share in cancer therapeutics due to factors such as advanced healthcare infrastructure, higher prevalence of cancer, increased awareness, and presence of leading pharmaceutical and biotechnology companies. Europe follows closely, driven by similar factors. However, the Asia-Pacific region is anticipated to grow at the fastest rate owing to a large patient population, increasing healthcare expenditure, and improving healthcare infrastructure.

One key trend shaping the market is the growth in personalized medicine and targeted therapies. These treatments, which work by targeting specific genetic or molecular characteristics of cancer cells, often have fewer side effects and can be more effective than traditional chemotherapy. This trend is driving significant investment and research in the sector, leading to the development of innovative therapies.

Immunotherapy is another significant growth area within the cancer therapeutics market. Treatments such as immune checkpoint inhibitors and CAR-T cell therapies have shown remarkable effectiveness against certain types of cancer, leading to high demand and substantial market growth.

Additionally, the rise in collaborative efforts between pharmaceutical companies and academic or research institutes accelerates the speed of clinical trials and drug development, further propelling the market. Numerous promising cancer drugs are currently in various stages of the pipeline, reflecting the active state of innovation in this field.

However, the market also faces challenges. The high cost of cancer drugs and disparities in access to advanced therapies, particularly in low- and middle-income countries, are significant hurdles. Furthermore, the complexity of drug development, including the need for rigorous clinical trials and the high rate of attrition for potential new drugs, poses ongoing challenges.

Overall, the global cancer therapeutics market is expected to continue its growth trajectory in the coming years, buoyed by advancements in science, technology, and a better understanding of the molecular mechanisms of cancer. Despite the challenges, the market is poised for significant transformation, offering hope for better cancer treatments and outcomes.

Key Players in the Global Cancer Therapeutics Market


The report gives an in-depth analysis of the key players involved in the cancer therapeutics market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Celgene Corporation
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Bayer AG
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Genentech
  • Seattle Genetics, Inc.
  • Aimmune Therapeutics
*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Cancer Therapeutics Market Overview
6.1 Global Cancer Therapeutics Market Historical Value (2016-2022)
6.2 Global Cancer Therapeutics Market Forecast Value (2023-2031)
7 Global Cancer Therapeutics Market Landscape
7.1 Global Cancer Therapeutics Company Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cancer Therapeutics Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Cancer Type
7.2.5 Analysis by Distribution Channel
8 Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cancer Therapeutics Market Segmentation
11.1 Global Cancer Therapeutics Market by Therapy Type
11.1.1 Market Overview
11.1.2 Chemotherapy
11.1.3 Immunotherapy
11.1.3.1 Checkpoint Inhibitors
11.1.3.2 Car-T Cell Therapy
11.1.3.3 Cancer Vaccines
11.1.3.4 Cytokine Therapy
11.1.4 Targeted Therapy
11.1.4.1 Tyrosine Kinase Inhibitors
11.1.4.2 Monoclonal Antibodies
11.1.4.3 Proteasome Inhibitors
11.1.5 Hormonal Therapy
11.1.6 Radiation Therapy
11.1.7 Stem Cell Transplant
11.1.8 Gene Therapy
11.1.9 Other Emerging Therapies
11.2 Global Cancer Therapeutics Market by Drug Class
11.2.1 Market Overview
11.2.2 Alkylating Agents
11.2.3 Antimetabolites
11.2.4 Antitumor Antibiotics
11.2.5 Topoisomerase Inhibitors
11.2.6 Mitotic Inhibitors
11.2.7 Hormone Therapies
11.2.8 Immune Checkpoint Inhibitors
11.2.9 Others
11.3 Global Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Intravenous
11.3.4 Subcutaneous
11.3.5 Intramuscular
11.3.6 Topical
11.3.7 Others
11.4 Global Cancer Therapeutics Market by Cancer Type
11.4.1 Market Overview
11.4.2 Lung Cancer
11.4.3 Breast Cancer
11.4.4 Prostate Cancer
11.4.5 Colorectal Cancer
11.4.6 Skin Cancer
11.4.7 Blood Cancer (Leukemia, Lymphoma, etc.)
11.4.8 Gastrointestinal Cancer
11.4.9 Gynecological Cancer
11.4.10 Others
11.5 Global Cancer Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital pharmacies
11.5.3 Retail pharmacies
11.5.4 Online pharmacies
11.5.5 Specialty pharmacies
11.6 Global Cancer Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cancer Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 AstraZeneca
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Bristol-Myers Squibb
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Eli Lilly and Company
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 F. Hoffmann-La Roche AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 GlaxoSmithKline
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Johnson & Johnson
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Merck & Co., Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis International AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Pfizer Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Sanofi
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Takeda Pharmaceutical Company Limited
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Celgene Corporation
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Amgen Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Gilead Sciences, Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Bayer AG
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 AbbVie Inc.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Regeneron Pharmaceuticals, Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Genentech
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Seattle Genetics, Inc.
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Aimmune Therapeutics
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Global Cancer Therapeutics Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings